Watch Live

Tweet TWEET

Kemwell Biopharma Acquires Development Services Firm Cirrus Pharmaceuticals, Inc., USA

 Kemwell Biopharma Acquires Development Services Firm Cirrus Pharmaceuticals,
                                  Inc., USA

  PR Newswire

  BANGALORE and DURHAM, USA, July 26, 2013

BANGALORE and DURHAM, USA, July 26, 2013 /PRNewswire/ --

Kemwell Biopharma, a leading global bio/pharmaceutical contract services
company headquartered in Bangalore, India, announced today that it has
acquired Cirrus Pharmaceuticals, Inc., a contract development services company
based in Research Triangle Park, NC, USA.

Cirrus is a highly reputed contract product development organization.It has
been serving the needs of the global pharmaceutical industry for over 15
years. Since its inception in 1997, Cirrus has established a strong reputation
for its development expertise in inhalation, parenteral, transdermal, topical
and liquid dosage forms. It also offers stand-alone analytical services
including stability studies.

"Kemwell's corporate objective is to build a leading global bio/pharmaceutical
contract services company," said Anurag Bagaria, Chairman and MD of Kemwell.
"Cirrus will complement the existing contract services offered by Kemwell with
early stage innovative product development. Kemwell will now provide customers
with a complete solution from early development in the US to commercial
manufacturing in Kemwell's EMA, FDA and PMDA approved facilities in India and
Sweden."

Dr. Ninad Deshpanday, President R&D at Kemwell said, "With Cirrus' development
capabilities and Kemwell's manufacturing expertise, we will be able to develop
products with faster time-to-clinic and significant cost savings for our
customers."

Cirrus' President, Dr. Anthony Hickey added, "This acquisition is a testament
to the tremendous value our talented employees have created for Cirrus over
the past several years.The acquisition will transform Cirrus into a global
player in R&D services by significantly strengthening our capabilities in
inhalation R&D and increasing offerings in other areas such as oral solids
dosage forms.The Cirrus team looks forward to joining the Kemwell family and
continuing to provide the high customer satisfaction it always has."

About Cirrus

Cirrus Pharmaceuticals is a contract research and product development company
located in Research Triangle Park, North Carolina, USA. Cirrus can assist or
manage projects as needed by providing a broad array of R&D services including
physical and chemical characterization, formulation development, stability
testing, container/closure selection, process development, scale-up and
technical transfer for inhaled, nasal, oral, parenteral, topical and
transdermal products. Services can include submission-ready regulatory
documentation and assistance with regulatory submission questions.

About Kemwell Biopharma Pvt. Ltd.

Kemwell Biopharma Pvt. Ltd., with its head office in Bangalore, India is a
pure play contract development and manufacturing company. The company develops
and manufactures bio/pharmaceuticals for some of the world's top
pharmaceutical companies, including Bayer, Boehringer Ingelheim,
GlaxoSmithKline, Merck KGaA, Novartis and Pfizer. Kemwell is one of India's
largest CDMO of bio/pharmaceuticals with over 30 years' experience. The
company employs more than 1200 employees worldwide and has seven production
facilities and state-of-the art research and development laboratories in India
and Sweden. Kemwell is an approved bio/pharmaceutical manufacturer in over 80
countries including the American, European, Japanese and Indian markets.

Read more about Kemwell on www.kemwellbiopharma.com

Primary Media Contact: Karan Bagaria, karan.bagaria@kemwellpharma.com ,
91-98454-00011

Secondary Media Contact: Ninad Deshpanday, ninad@kemwellpharma.com ,
1-919-6307176

Contact: PRN
 
Press spacebar to pause and continue. Press esc to stop.